Loading clinical trials...
Loading clinical trials...
A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination With Pembrolizumab in Subjects With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
Conditions
Interventions
ADXS-503
Pembrolizumab
Locations
9
United States
City of Hope
Duarte, California, United States
University of California, Los Angeles
Los Angeles, California, United States
Emory University
Atlanta, Georgia, United States
Illinois CancerCare, P.C.
Peoria, Illinois, United States
The University of Kansas Medical Center
Westwood, Kansas, United States
Atlantic Health System, Carol G Simon Cancer Center
Morristown, New Jersey, United States
Start Date
February 12, 2019
Primary Completion Date
February 22, 2022
Completion Date
February 22, 2022
Last Updated
June 4, 2024
NCT07219251
NCT06405230
NCT05815927
NCT04940936
NCT06912087
NCT04868162
Lead Sponsor
Advaxis, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions